A wearable device for treating migraines using transcutaneous peripheral nerve stimulation, comprising: a first peripheral nerve effector configured to be placed on a skin surface proximate a median nerve of an arm or a wrist of a patient; a second peripheral nerve effector configured to be placed on a skin surface proximate a nerve other than the median nerve of the arm or the wrist of the patient; and a controller configured to: receive data relating to the patient; generate parameters of a first electrical stimulation signal and/or a second electrical stimulation signal based on the data relating to the patient; transcutaneously deliver the first electrical stimulation signal to the first peripheral nerve effector to stimulate the median nerve; and transcutaneously deliver the second electrical stimulation signal to the patient via the second peripheral nerve effector, wherein the data relating to the patient comprises information related to a number of episodes of symptoms, wherein said symptoms include one or more of: unilateral throbbing cranial pain, sensory sensitivity to light, sound, and smell, nausea, and dysfunction of autonomic, cognitive, emotional, and motor systems; wherein if more episodes occur in one day, the first and/or second electrical stimulation signal can be increased by increasing an amplitude of the stimulation, a duration of the stimulation, or a number of treatment sessions; and wherein the controller is configured such that transcutaneously delivering the first electrical stimulation signal and the second electrical stimulation signal is therapeutically effective to modify at least one neural pathway associated with migraine. a first peripheral nerve effector configured to be placed on a skin surface proximate a median nerve of an arm or a wrist of a patient; a second peripheral nerve effector configured to be placed on a skin surface proximate a nerve other than the median nerve of the arm or the wrist of the patient; and a controller configured to: receive data relating to the patient; generate parameters of a first electrical stimulation signal and/or a second electrical stimulation signal based on the data relating to the patient; transcutaneously deliver the first electrical stimulation signal to the first peripheral nerve effector to stimulate the median nerve; and transcutaneously deliver the second electrical stimulation signal to the patient via the second peripheral nerve effector, wherein the data relating to the patient comprises information related to a number of episodes of symptoms, wherein said symptoms include one or more of: unilateral throbbing cranial pain, sensory sensitivity to light, sound, and smell, nausea, and dysfunction of autonomic, cognitive, emotional, and motor systems; wherein if more episodes occur in one day, the first and/or second electrical stimulation signal can be increased by increasing an amplitude of the stimulation, a duration of the stimulation, or a number of treatment sessions; and wherein the controller is configured such that transcutaneously delivering the first electrical stimulation signal and the second electrical stimulation signal is therapeutically effective to modify at least one neural pathway associated with migraine. receive data relating to the patient; generate parameters of a first electrical stimulation signal and/or a second electrical stimulation signal based on the data relating to the patient; transcutaneously deliver the first electrical stimulation signal to the first peripheral nerve effector to stimulate the median nerve; and transcutaneously deliver the second electrical stimulation signal to the patient via the second peripheral nerve effector, wherein the data relating to the patient comprises information related to a number of episodes of symptoms, wherein said symptoms include one or more of: unilateral throbbing cranial pain, sensory sensitivity to light, sound, and smell, nausea, and dysfunction of autonomic, cognitive, emotional, and motor systems; wherein if more episodes occur in one day, the first and/or second electrical stimulation signal can be increased by increasing an amplitude of the stimulation, a duration of the stimulation, or a number of treatment sessions; and wherein the controller is configured such that transcutaneously delivering the first electrical stimulation signal and the second electrical stimulation signal is therapeutically effective to modify at least one neural pathway associated with migraine.